{
  "docId": "019de075-cd17-7685-9273-fb1c731af40f",
  "docSlug": "16b2d7592f4634ac7cd717a996934f07",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 35,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide illustrates how findings from one study (PIFR-1) informed the design of a subsequent study (PIFR-2) by narrowing the patient population to GOLD 3/4, resulting in statistically significant improvement.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/13",
  "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f",
  "deckJsonHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f.json",
  "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.23,
        "x": 0.18,
        "y": 0.16
      },
      "kind": "callout",
      "text": "ITT: GOLD 2/3/4 PIFR < 60 L/min",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2130f9bb-1d5f-4095-89fc-8f20a7dfb270",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.23,
        "x": 0.64,
        "y": 0.18
      },
      "kind": "callout",
      "text": "GOLD 3/4",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84ed305a-e0ef-4c66-8dcb-2557ebf5867c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.75,
        "x": 0.13,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Comparison of Trough FEV1 results between two cohorts",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d86d67a1-e343-473f-9982-e87ffbea2eae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Chronic Obstr Pulm Dis. 2019; 6(4): 321–331. Note: The ns shown are the numbers in the analysis set or subset...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aaa99547-3928-4b5e-b3be-e8e14e1ece77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.67,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "PIFR-1 Experience Informed PIFR-2 Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a005fde3-8666-47e7-a0d1-a842e83455a5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "abb2f5ee-feba-4191-9532-1e4b0e7e0f23",
      "evidence": "The slide explicitly contrasts a prior study result with a subsequent study design to show improvement.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 11,
      "beatId": "ae4646ce-73d8-418d-9390-888b787632a7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f",
      "evidence": "The document highlights the significant unmet need for MSA patients",
      "position": 1,
      "objective": "Emphasizing the cost of inaction for MSA patients",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}